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ABSTRACT 47 
 48 
Objective: Our primary objective is to re-visit the tuberculosis and leprosy cross-immunity hypothesis 49 
through the careful integration of immunology and paleopathology. Methods: Using an integrated 50 
theoretical analysis that evaluates clinical literature on human innate immunological responses, 51 
paleomicrobiology, bioarchaeology, and paleopathology, we develop a multifactorial model. Results: Past 52 
populations do not represent homogeneous immunological landscapes, and therefore it is likely that leprosy 53 
in Medieval Europe did not uniformly decline due to cross-immunity. Conclusions: We recommend that 54 
bioarchaeological reconstructions of past disease experience take into consideration models that include 55 
variation in immune function based on past environments and social contexts. This provides a unique 56 
opportunity to conduct comprehensive analyses on complex immunological processes. Significance: 57 
Extrapolating results from experimental immunology to larger populations elucidates complexities of 58 
disease cross immunity and highlights the importance of synthesizing archaeological, social, 59 
paleopathological and biological data as a means of understanding disease in the past. Limitations: All 60 
extrapolations from data produced from in vitro studies to past populations, using living donors, pose 61 
significant limitations where, among other factors, the full reconstruction of past environmental and social 62 
contexts can frequently be sparse or incomplete. Suggestions for Future Research: To reduce the 63 
limitations of integrating experimental immunology with bioarchaeological reconstructions (i.e. how to use 64 
skeletal samples to reconstruct inflammatory phenotypes), we propose that osteoimmunology, or the study 65 
of the interplay between immune cells and bone cells, should be considered a vital discipline and perhaps 66 
the foundation for the expansion of paleoimmunology.  67 
 68 
1. INTRODUCTION 69 
Leprosy and tuberculosis (TB) are close related infectious diseases that can be associated with 70 
similar social, ecological, and biological factors such as poverty, poor access to health care, 71 
malnourishment, urban living, and compromised immune systems.  Leprosy, also known as 72 
Hansen disease, is a chronic infectious disease that, depending on the host immunological response 73 
and if left untreated, can slowly progress and cause debilitating impairments and disabilities 74 
associated with peripheral nerve damage and cutaneous lesions. Of all mycobacterial species, 75 
Mycobacterium leprae has humans as its natural host, although leprosy-like disease has been 76 
described in non-human primates and armadillos (introduced via humans in the second) (Monot et 77 
al 2005; Truman 2005; Walsh et al.1988), occasionally in other animals, and most recently in red 78 
squirrels in the UK (Avanzi et al. 2016). Leprosy, in regard to host immune competence, can show 79 
a broad spectrum of clinical signs and symptoms, where at one end patients with tuberculoid 80 
leprosy (TL) express an extensive cell mediated immune response, and at the other patients with 81 
lepromatous leprosy (LL) have a cell mediated response or innate response significantly reduced 82 
(Kapplan 1994). However, it is recognized that a continuous spectrum exists between the polar 83 
states (Ridley and Jopling 1966).The exact mechanism of transmission of leprosy is still not clear 84 
but household and other prolonged close contact could be involved in the spread of leprosy where 85 
the nose and the skin are the most common microbe entrance points (Hussain 2007; WHO 2016). 86 
The TB pathogens, or organisms within the Mycobacterium tuberculosis complex, will infect the 87 
host through the lungs or the gastrointestinal tract, and the symptoms and progression of the 88 
disease vary according to where the infection first expresses itself (WHO 2017b). Pulmonary 89 
infection commonly causes shortness of breath, chest pain, cough, loss of blood and weight. 90 
Gastrointestinal infection also includes loss of blood and weight as well as abdominal pain 91 
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(Holgate and Frew, 2002). TB and leprosy have been known to be human pathogens for millennia 92 
(Spigelman and Donoghue 2003; Larsen 2015), where some researchers propose that TB is a 93 
younger disease, having evolved in the Neolithic (Bos et al. 2014; Kay et al. 2015), whereas others 94 
believe it could be older (Comas et al. 2013). Skin testing with tuberculin (extract of the tubercle 95 
bacillus) shows that up to one third of the world’s population has been infected with M. 96 
tuberculosis and recently, due to immuno-compromised individuals and multi-resistant strains, TB 97 
has re-emerged in some regions (WHO 2017b). Leprosy is still endemic in some regions such as 98 
Southeast Asia and South America but it has shown a significant decline due to a combination of 99 
factors such as improved standards of living, relatively efficacy of multi-drug therapies, erosion of 100 
social stigma, albeit slow, and to a certain extent the protective capacity of the TB vaccine bacillus 101 
Calmette-Guérin-BCG (Stanford and Stanford 2002). However, social stigma still persists and can 102 
affect whether a person accesses diagnosis and receives care and treatment, apart from the fact that 103 
a diagnosis affect their lives in considerable ways (Kaehler et al. 2015). In terms of vaccine 104 
protection, the efficacy of the BCG vaccine can be variable. For example, a meta-analysis of the 105 
role of the BCG vaccine in the prevention of leprosy used seven experimental and 19 observational 106 
studies; where the latter showed an overall protective effect of 26%, and the former 61% (Setia et 107 
al. 2006). Recent findings challenged the idea that only acquired immune responses can develop 108 
immunological memory, proposing that innate responses can also develop immunological 109 
memory, especially non-specific cross protection against re-infection (Netea et al. 2016; Quintin et 110 
al. 2014). Furthermore, an emerging discipline such as ecological immunology is teaching us how 111 
multiple ecological and social factors can affect innate or acquired immune responses (McDade 112 
2003; McDade 2005a).  113 
Therefore, we consider that re-visiting the TB and leprosy cross-immunity hypothesis is now 114 
necessary, and particularly exploring how an emerging discipline such as ecological immunology 115 
and new findings on innate immune memory can expand our understanding on TB-leprosy cross 116 
immunity. Ultimately, we propose a multifactorial model that addresses how ecological 117 
immunology can help to contribute more comprehensive paleopathological reconstructions. In 118 
addition, this will help to build a model where (depending on different biological and ecological 119 
factors) individuals who are able to develop protective cross immunity could be recognized.    120 
1.1 Cellular immune responses to leprosy and tuberculosis. 121 
The immune system reacts to infection via two mechanisms: the cellular response, which is 122 
commonly associated with the innate immune response and involves white blood cells where some 123 
cells (called phagocytes) recognize, engulf, and destroy pathogens; and the humoral response, 124 
which is commonly associated with the acquired immune response, and involves the secretion of 125 
antibodies. These two responses work in concert and effectively protect us from infection through 126 
a complex multilayered network of cooperation that blurs the distinction between innate and 127 
acquired responses (Danilova 2008). While both mechanisms are involved against TB and leprosy 128 
(Britton and Lockwood 2004; North and Jung 2004; Sansonetti and Lagrange 1981), in this article, 129 
we focus our attention on the cellular response when reconsidering the cross immunity hypothesis. 130 
The innate response plays a crucial role in leprosy infection and, depending on its strength and 131 
efficacy, leprosy will progress into different clinical stages (Cooper et al. 2011; Modlin 2010; 132 
Montoya and Modlin 2010). In the final discussion we propose to incorporate new information on 133 
innate immune memory and the influence of environmental factors that could change our 134 
understanding of leprosy-TB cross immunity, and contribute to debates about the relationship 135 
between these two infectious diseases in the past. 136 
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As mentioned above, leprosy can produce a broad spectrum of clinical symptoms: patients with TL 137 
express an extensive cell mediated immune response, and in patients with LL, the cell mediated 138 
response or innate response is significantly reduced (Kaplan 1994).  Higher expression of Toll-like 139 
receptor 2/1 heterodimer have been detected in TL, and both ends of the leprosy spectrum (TL and 140 
LL) differentially stimulate the production of pro-inflammatory cytokines such as tumor necrosis 141 
factor-TNFα (Modlin 1994). However, a significantly higher expression of interleukin-2 (IL-2) 142 
and interferon gamma (IFNγ) associated with a Th1 inflammatory response was detected in 143 
tuberculoid lesions commonly present in TL. This elevated expression of pro-inflammatory 144 
cytokines could be associated with an extensive cellular response and resistance to growth of M. 145 
leprae in TL. We must consider that the differential cell mediated and cytokine responses between 146 
TL and LL indicate that leprosy is not a static disease but a dynamic disease in which immune 147 
shifts alter the disease progression and clinical symptoms (Modlin 1994). While, overall, the 148 
human immune response to leprosy is mostly based on cellular immunity and not humoral 149 
(acquired) immunity (Hunter and Thomas 1984), in some patients (LL)  a polyclonal lymphocyte 150 
B response has also been detected, leading to an acquired or humoral reaction (Nath et al. 2015).  151 
TB commonly infects the host through the lungs or the gastrointestinal tract, and the innate 152 
response is crucial in containing the infection, where (as in leprosy) IFNγ and TNFα are two of the 153 
most important cytokines involved in the inflammatory response (Cavalcanti et al. 2012; van 154 
Crevel et al. 2002). In individuals with latent TB, TNFα plays a crucial role and acts on a variety 155 
of different immune cells (Cavalcanti et al. 2012; Lin and Flynn 2010). Interestingly, increased 156 
levels of TNFα have been detected when in vitro cultures of peripheral blood mononuclear cells 157 
(PBMCs) from patients with pulmonary TB were exposed to mycobacterial antigens (Al-Attiyah et 158 
al. 2012; Dlugovitzky et al. 2000). Both cytokines, IFNγ and TNFα, act in the early stages of 159 
infection to conduct the innate response and at the later stage to sustain and regulate it (Cooper et 160 
al. 2011). Interestingly, in a recent study, it was shown that different mycobacterial strains will 161 
affect the interferon response (Wiens and Ernst 2016). Ultimately, a constant battle will unfold 162 
between the host and the pathogen that will recruit innate and acquired immune mechanisms. It has 163 
been suggested that the exacerbated inflammatory response (innate response) present in psoriasis 164 
could have also reduced the clinical progression of leprosy, leading to the argument that the 165 
“psoriasis genotype” expanded in different human populations under the selection pressure of 166 
historical leprosy epidemics (Bassukas et al. 2012). Moreover, it has been proposed that latent 167 
infections can create a polarized cytokine environment and develop a prolonged state of cross 168 
protection when the host faces different pathogens (Barton et al. 2007). Relevant for our analysis, 169 
in cases of latent or dormant TB, most patients mount a strong immune response, and contain but 170 
do not eliminate the infection (Ferraz et al. 2006; Flynn and Chan 2001).   171 
1.2 Why propose cross-immunity between leprosy and tuberculosis? 172 
The family Mycobacteriaceae contains more than 200 species, where some species are pathogenic 173 
to humans and other animals (Stone et al. 2009). It is known that different species of the genus 174 
mycobacteria share many antigens, and therefore it can be expected that there would be a complex 175 
pattern of immunological interaction between concomitant infections (or casual exposure to)  176 
different mycobacterial species (Fine 1984). While the similarities and potential antagonism of TB 177 
and leprosy infections have previously been identified (Rogers 1924), Roland Chaussinand is 178 
mostly credited with proposing the hypothesis on cross-immunity between TB and leprosy. He 179 
proposed a theory of disease antagonism, and suggested that this interaction could partially explain 180 
the decline of leprosy in areas where TB had become prevalent (Chaussinand 1953; Chaussinand 181 
5 
 
1955). Lowe and McNulty also highlighted that for more than 20 years different researchers had 182 
discussed the idea that individuals that are immune to TB may show some degree of immunity to 183 
leprosy (Lowe and McNulty 1953). These authors pointed out, as Chaussinand did, that the advent 184 
of the use of the BCG vaccination (derived from Mycobacterium bovis) as a prophylactic measure 185 
against TB showed that immunity to leprosy developed in some individuals (Chaussinand 1955; 186 
Lowe and McNulty 1953). Perhaps the most conclusive scientific evidence was based on people 187 
who were not exposed to the leprosy pathogen but were infected with M. tuberculosis, or received 188 
the BCG vaccine and showed a later positive reaction to the lepromin test (based on the injection 189 
of inactivated M. leprae pathogen) (Fernandez 1939; Fernandez 1957). Simply put, the cross 190 
reactions could be explained by early immunological exposure to one pathogen that facilitated the 191 
immune recognition of a secondary infection produced by a pathogen antigenically related to the 192 
first one.  193 
During the 20th century, while still recognizing the potential role of cross-immunity, other factors 194 
were considered as playing a role in TB and leprosy interaction. It was proposed, from a social and 195 
sanitary approach, that as communications improve in human societies but sanitation lags behind, 196 
leprosy can affect the population, and as TB penetrates the community, leprosy tends to decline 197 
(Muir 1957). Interestingly, because in some areas where humans showed some type of cross-198 
sensitivity but where leprosy was not present, it was suggested that the presence of non-pathogenic 199 
mycobacteria could be also involved, inducing some form of priming of the immune system (Muir 200 
1957). In the case of the lepromin test, a curious observation is that this reaction gives positive 201 
results mainly for the resistant form of leprosy (TL) but it also shows positivity in individuals that 202 
have had no contact with leprosy, and perhaps may be regarded as an allergic non-specific reaction 203 
(Fernandez 1939; Lowe and McNulty 1953; Muir 1957). Moreover, as discussed above, some 204 
differences in responses to tuberculin or lepromin tests were due to exposure to mycobacteria other 205 
than M. tuberculosis or M. leprae as well as other co-infections (i.e. Candida albicans), and also 206 
due to the clinical status (healthy vs. non-healthy) of the individuals considered in those studies 207 
(Sartwell 1968). Many clinical trials during the last decades have shown a positive correlation 208 
between BCG vaccination and later protection against leprosy (Kinnear Brown and Sutherland 209 
1968; Ohara et al. 2000; Rahete et al. 2007; Roche et al. 2001; Rodrigues et al. 2007; Shepard 210 
1966; Zodpey et al. 2005), and in the last decades, two meta-analyses provided more support for 211 
the correlation (Merle et al. 2010; Setia et al. 2006).  212 
Not all studies have shown BCG protection against leprosy, but we should consider that different 213 
factors such as in vivo models (mouse or human), the human population chosen for study, BCG 214 
dose quantity, and the timing and age of the vaccination can affect the outcome of this interaction, 215 
thus revealing the complex and heterogeneous interaction between pathogen and host. It was 216 
suggested that the lack of experimental and clinical conclusiveness regarding the protective effect 217 
of BCG vaccination against leprosy was due in part to the slow-progressing nature of leprosy, its 218 
long silent incubation period, and relatively low infection rate (Hunter and Thomas 1984). In 219 
addition to the use of the BCG vaccination as potential proof of cross-immunity between TB and 220 
leprosy, antigens ESAT-6 and CFP-10 expressed in most pathogenic strains from the M. 221 
tuberculosis complex have homologous proteins in M. leprae that show significant cross reactivity 222 
in human immune cells (Geluk et al. 2002; Geluk et al. 2004). Recently, new candidate vaccines 223 
for TB, ID83/GLA-SE and ID93/GLA-SE, generated inflammatory responses in both TB and 224 
leprosy (TL) patients, suggesting that due to this cross-reactivity these vaccines could be also used 225 
as an additional control for leprosy (Duthie et al. 2014).  226 
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For example, in India in 2011, it was reported as 0.02% of all concomitant infections (TB and 227 
leprosy) per 100,000 population (Rawson et al. 2014), and it was suggested that one potential 228 
explanation for this apparent decline in concomitant infection that should not be ruled out could be 229 
the protective effects of cross immunity (Rawson et al. 2014). Furthermore, in contemporary 230 
Brazil, one possible factor for the recent decline in co-infected people, as well as the decline in the 231 
detection rate of leprosy, is BCG vaccination (Trindade et al. 2013). 232 
1.3 Leprosy decline in Western Medieval Europe and the case for disease interaction. 233 
When formalizing the cross immunity hypothesis between TB and leprosy, Roland Chaussinand in 234 
his seminal paper called not only for more experimental work but also finding evidence in human 235 
populations were we can study the time of exposure, in the lifetime of an individual or population, 236 
of both diseases (Chaussinand 1953). In Western Europe, while TB has remained at epidemic 237 
proportions, leprosy is rarely found today (Hussain 2007). The reason for the significant decline of 238 
leprosy as an endemic infectious disease in Western Europe after the 13th century is still unclear. 239 
Some bioarchaeologists have tried to reconstruct the interaction of both infectious diseases in 240 
antiquity (Manchester 1984; Manchester and Roberts 1989; Roberts 2002). While considering the 241 
limitations of using the evidence from skeletal remains to achieve this task, but also the presence 242 
of ecological and social factors that could have been responsible for the decline of leprosy in 243 
Medieval period in Europe (12th-16th centuries), it was proposed that it could be possible to 244 
extrapolate contemporary clinical findings to Medieval populations and argue that cross-immunity 245 
did also play a role in the leprosy decline associated with a rise in TB in Medieval period in 246 
Europe (Manchester 1984). Social factors will also have played a role, such as disparities in the 247 
presence of leprosy in the Medieval period, inferred from the rise and decline of leprosy hospitals 248 
(Blondiaux et al. 2015), but it could also reflect changes in beneficence of the wealthy 249 
(Manchester and Roberts 1989).  250 
It is likely, when considering the continental decline of a long lasting chronic infection such as 251 
leprosy, that more than one factor should be considered, and perhaps multiple factors played a 252 
significant role at different times and in different regions. Hunter and Thomas (1984) summarized 253 
most factors that should be considered: 1. Antigenic shift resulting in loss of pathogenicity; 2. 254 
Attenuating effects of isolation and quarantine; 3. Direct or indirect mortality caused by acute 255 
infections such as Medieval plague epidemics; 4. Dietary changes; 5. Clothing habits; 6. Changes 256 
in housing and sanitation; 7. Interaction with other chronic infections such as TB (Hunter and 257 
Thomas 1984).  258 
When modeling transmission in TB and leprosy, Lietman and colleagues (1997) tried to assess the 259 
degree of cross-immunity that would be necessary for M. tuberculosis to compete and eliminate M. 260 
leprae, revealing that (while centuries will be required) if the reproductive rate of leprosy was 261 
relatively slow, TB could have played a significant role in the disappearance of leprosy from 262 
western Europe (Lietman et al. 1997). Interestingly, while still controversial due to some doubts 263 
about using only the IS6110 DNA marker to detect ancient M. tuberculosis (Muller et al 2016), a 264 
study conducted to evaluate the existence and relationship of both pathogens in archaeological 265 
human remains showed that several individuals with skeletal signs of leprosy were found to 266 
contain DNA from both pathogens (Donoghue et al. 2005). The authors of this study concluded 267 
that the impairment in cell mediated immune response found in LL (commonly identified in 268 
archaeological remains), coupled with social factors, would lead to a re-activation of latent TB and 269 
perhaps induce a speedier death and decline in the number of individuals with leprosy (Donoghue 270 
et al. 2005). Recently, another study using a mathematical approach for modeling the 271 
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epidemiological consequences of the co-infection hypothesis supported by Donoghue and 272 
colleagues, concluded that the co-infection hypothesis should be considered a significant 273 
alternative to the cross-immunity hypothesis proposed by Chaussinand (Hohmann and Voss-274 
Bohme 2013). Other researchers have studied the incidence of both infections and searched for 275 
evidence of cross-immunity in populations from Texas, USA, dating from the last two centuries. 276 
They found few significant negative correlations in the data (TB increase and leprosy decrease); on 277 
the contrary, some data showed an inverse correlation, or in some cases both diseases were 278 
declining at the same time (Wilbur et al. 2002). However, debates on the interaction of these two 279 
diseases in Medieval Europe is far from closed, as demonstrated in a recent symposium on past, 280 
current, and future research on leprosy, organized during an Annual Meeting of the American 281 
Association of Physical Anthropologists (2014), where three different presentations explored and 282 
re-analyzed the TB-leprosy cross immunity hypothesis with partial antagonizing conclusions 283 
(cross immunity did or did not play a role in leprosy decline in Medieval Europe) (Donoghue et al. 284 
2014; Roberts 2014; Wilson et al. 2014).  285 
Whilst not ruling out any hypothesis for the significant decline of leprosy at the end of the 286 
Medieval period in Europe, in this paper we will focus our attention on the cross-immunity TB-287 
leprosy hypothesis. In so doing, we will propose a novel multifactorial model that includes social 288 
and ecological elements that address most of the factors proposed by Hunter and Thomas (1984). 289 
This ultimately affects the reconstruction of immune competence of each individual when 290 
considering novel findings in innate immune memory and plasticity. 291 
1.4 Innate immune memory: trained cell mediated immunity? 292 
Immune responses in humans are usually divided into innate responses and acquired or specific 293 
responses. While it has been recognized that these two responses work in concert and effectively 294 
protect us from infection through a complex multilayered network of cooperation (Danilova 2008), 295 
both responses are commonly associated with different cell components and mechanisms. The 296 
innate response usually presents a quick cellular and phagocytic response, and the acquired 297 
response shows a more delayed cellular and humoral mechanism that can present a specific 298 
immunological memory to future infections. However, lately, the statement that the innate cellular 299 
mediated responses lack memory has been reconsidered (Quintin et al. 2014).  300 
In recent years, it has been proposed that the term “trained immunity” should be used to describe 301 
enhanced innate host defense mechanisms in those organisms that lack acquired immune 302 
responses, but mounting evidence is showing that similar innate memory can be found in 303 
mammals (Netea 2013; Netea et al. 2011). It is important to point out that this “trained immunity” 304 
against reinfection can be applied to the same or different pathogen.  305 
Interestingly, it is well recognized that infection by M. tuberculosis can impact subsequent 306 
infections such as HIV and malaria (Berry et al. 2010; Havlir  and Barnes 1999; Whalen et al. 307 
1995). Therefore, depending on different cofounding factors, the impact of TB infection can 308 
benefit or harm the host (Stelekati and Wherry 2012). During TB infection an elevated expression 309 
of pro-inflammatory cytokine IFNγ may protect a person from subsequent Plasmodium infection 310 
(Page et al. 2005). Additionally, commensal bacteria can modulate host innate immune responses 311 
to unrelated pathogens and help in mounting optimal antiviral immune responses (Abt et al. 2012). 312 
Detecting microbial patterns by different immune cells involved in the innate responses not only 313 
leads to cell activation but also can lead to reshaping their response to a subsequent microbial 314 
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insult (Quintin et al. 2014). For example, the non-specific BCG protective effect can also be 315 
attributable to activated macrophages (Van't Wout et al. 1992). 316 
While both immune responses, innate and acquired, are involved in TB and leprosy (Flynn and 317 
Chan 2001; Modlin 1994; Nath et al. 2015), perhaps we can incorporate the “trained immunity” of 318 
the innate responses as another factor when exploring the potential cross-protection between TB 319 
and leprosy. Ultimately, such a proposal calls for more exploration of how exposure to one 320 
pathogen can affect or shift the inflammatory responses (i.e.: pro-inflammatory cytokine 321 
expression) when the same cells are subsequently exposed to another pathogen, meaning: can we 322 
“train” immune cells by early exposure to M. tuberculosis, and later modify the cell response to M. 323 
leprae?. Clearly, the results of such in vitro analysis should be carefully applied when extrapolated 324 
to real humans with complex life histories. However, we consider that such extrapolation and 325 
discussion can benefit disciplines such as bioarchaeology and its subdiscipline, paleopathology, 326 
especially when proposing a multifactorial model to explore TB-leprosy cross immunity. Our 327 
ultimate goal is to explore a model where early and chronic exposure to one (or more) 328 
mycobacterial species can produce an inflammatory shift that either can generate protection to 329 
later leprosy infection, or push leprosy infection towards the TL end of its spectrum where a 330 
heightened cellular immunity is required (Figure 1). However, the final outcome of “training” of 331 
the innate immune responses to generate cross immunity will also be influenced by ecological and 332 
social factors. 333 
2. BUILDING A MULTIFACTORIAL MODEL 334 
The proposed model considers and discusses the existence of heterogeneous biosocial 335 
immunological landscapes, and takes special consideration of the following factors: the 336 
immunological spectrum of the innate response to TB; the role of other mycobacterial species; and 337 
the complexity of the paleopathological record as potential evidence. 338 
2.1 Consideration of the broad immunological spectrum of tuberculosis and the potential 339 
shift of the innate response against leprosy 340 
In TB, the type of immune response produced against M. tuberculosis will significantly influence 341 
the course of the disease, where the majority of infected immunocompetent individuals will remain 342 
healthy and asymptomatic. Usually these individuals mount a strong immune response but the 343 
bacteria persist in the host (Ferraz et al. 2006). During TB latent infection, the immune system 344 
controls the pathogen by means of “balanced inflammation” and generally causes minimal 345 
collateral damage, but in some patients TB can be characterized by non-resolved inflammation 346 
during latency and active phases (Kaufmann and Dorhoi 2013). Interestingly, immune function at 347 
the site of the infection may evolve differently than at the systemic level (Wallis and Ellner 1994). 348 
Ultimately, a “delicate” local and systemic cytokine equilibrium will be generated when 349 
controlling the progress and growth of M. tuberculosis. In murine models, it was shown that two 350 
antagonistic “protective” mechanisms are involved: first, the initial Th1 “protective” inflammatory 351 
response against the pathogen (where cytokines such as IFNγ and TNFα are involved); and second, 352 
a Th2 “protective” anti-inflammatory response to minimize tissue damage at the site of the 353 
infection (Wallis and Ellner 1994).  354 
Epidemiologically, M. tuberculosis is commonly characterized by long periods of persistence 355 
where the bacteria have developed the capacity to live in balance with the immune response. 356 
However, such a balance (especially on the host side), including that of Th1/Th2, can be impaired 357 
or compromised by different factors involving not only biological but ecological and behavioral 358 
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causes (Huynh et al. 2011). As proposed by one of the authors of this study (FC) we should 359 
consider how latent TB can systemically affect immune responses to other pathogens (Crespo et al. 360 
2017). Ultimately, we must consider how heightened systemic inflammatory responses (i.e. 361 
increased expression of TNFα) can affect subsequent infections (such as leprosy) not only due to 362 
acquired immune memory but because of over-reactive innate responses. Clearly, the potential 363 
spectrum of immunological responses observed in TB infection should be considered when 364 
analyzing its impact on a subsequent leprosy infection in a person.  365 
As mentioned above, in leprosy the elevated expression of pro-inflammatory cytokines, such as 366 
TNFα and IFNγ, is linked to extensive cellular response and resistance to growth of M. leprae 367 
leading to TL (Modlin 1994; Modlin 2010). While it was observed that TB infection can occur in 368 
people across the entire leprosy spectrum (Kumar et al. 1982), it can be suggested that TL through 369 
an enhanced innate or cellular response, could offer the best immunological context for cross 370 
immunity. However, it has been argued that LL is far from representing a generalized immune 371 
deficient system; on the contrary, some individuals could develop a hyper-immune state (Ell 372 
1987).  373 
Therefore, an enhanced inflammatory response due to active or latent TB, could have an impact on 374 
leprosy, but we should be careful when considering a particular stage of the clinical spectrum in 375 
leprosy. As expanded below (2.3), we must consider all leprosy stages, and if TB infection is 376 
active or latent (Figure 2). 377 
2.2 A consideration that more than one mycobacterial species can train the innate immune 378 
system. 379 
Usually, an infection generates a priming (“activation”) of innate immunity that normally declines 380 
after the infection is resolved. However, if we consider a chronic infection such as TB, there is an 381 
in vitro shift in the expression of different inflammatory proteins (Crespo et al. 2017). More than 382 
temporarily primed, the system can end in a steady-state level that remains enhanced and 383 
ultimately reprograms the innate response (Netea 2013).  384 
Exposure to M. tuberculosis and related environmental mycobacterial species (EM), could also 385 
generate a quasi-permanent shift of systemic immune responses and “train” the innate response. 386 
EM are not obligate pathogens but exhibit great variation in growth rates and virulence (Primm et 387 
al. 2004). The majority of human-EM interactions are transient, where the immune responses in 388 
most members of the population clear the bacteria from the body but this involves the release of 389 
potent immunomodulators  (Primm et al. 2004). Interestingly, it has recently been proposed that 390 
chronic exposure to EM can result in systemic tolerance toward these EM; moreover, it has been 391 
shown that the variable protective efficacy of the BCG vaccine is partially due to exposure to EM 392 
(Price et al. 2016). Perhaps, one of the most compelling pieces of evidence for “trained immunity” 393 
is developed by immunization of mice with the BCG vaccine where immunization also induces a 394 
T-cell independent protection against secondary infections with C. albicans or Schistosoma 395 
mansoni (Netea et al. 2016). Both, human immune cells infected or exposed to M. bovis can 396 
stimulate inflammatory cytokine expression (Atkinson et al. 2000). Recent findings from clinical 397 
investigation involving BCG vaccination and inflammatory responses suggest that BCG 398 
vaccination of leprosy patients (especially those with LL) induces immune cell activation, likely 399 
through “trained immunity”, that works as an additional protective mechanism (de Carvalho et al. 400 
2017; Kleinnijenhuis et al. 2014). 401 
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M. bovis infection in cattle and other animals represents a public health concern (O'Reilly and 402 
Daborn 1995), especially in populations where raw unpasteurized milk is still consumed. In past 403 
populations, M. bovis was probably a major source of TB infection in humans through the 404 
consumption of untreated dairy and other products, leading primarily to extra pulmonary or 405 
intestinal lesions (Manchester 1991; Smith et al. 2004), and increased cattle trade (and other 406 
animals) could have contributed to the spread of natural vaccination against leprosy (Boldsen and 407 
Mollerup 2006; Dangvard Pedersen et al 2018). While M. bovis is very rare in the 408 
paleomicrobiological record, this species was found in a group of Iron Age Siberian pastoralists 409 
associated with skeletal lesions typical for TB (Taylor et al. 2009). It was suggested that an 410 
unequal distribution of M. tuberculosis and M. bovis should be considered when exploring 411 
different communities, where crowded urban centers favored M. tuberculosis, and small agrarian 412 
communities favored M. bovis (Mays et al. 2001). 413 
Mycobacterium smegmatis is a saprophytic usually non-pathogenic EM (Tyagi and Sharma 2002) 414 
that can induce cytokine expression, mostly by macrophages, presumably being one the 415 
mechanisms by which these species are eliminated from the host (Beltan et al. 2000). Perhaps, 416 
chronic exposure to this species can also contribute to generate an enhanced quasi-permanent 417 
hyper-inflammatory phenotype. Recently it has been shown that some of its proteins can modify 418 
the mammalian host immune response (Sweeney et al. 2011) and in different animal models has 419 
been illustrated to induce immunomodulation as well as generate opportunistic infections 420 
(Bercovier and Vincent 2001). Remarkably, this mycobacterial species has been isolated from 421 
diseased animals, but more frequently from cattle (Bercovier and Vincent 2001). 422 
A recent study of ancient DNA of the M. tuberculosis complex, showed the complications 423 
(“interference”) generated by the presence of EM in skeletal remains that colonized the individual 424 
either pre- or post mortem (Müller et al. 2016). This line of evidence suggests that, as shown by 425 
different authors, we should take into consideration that previous exposure to EM might have 426 
played a natural vaccination role or a confounding role in the development of cross protection 427 
(Fine 1995; Lietman et al. 1997; Wilbur et al. 2002). Therefore, it cannot be ruled out the potential 428 
role of other mycobacterial species as contributory factors in “training” or at least priming the 429 
innate responses. Moreover, in the last decades, the risk of human M. bovis infection is increasing 430 
in populations with a high prevalence of HIV infection (Mfinanga et al. 2004; O'Reilly and Daborn 431 
1995; Thoen and LoBue 2007). 432 
2.3 Limitations of paleomicrobiological and bioarchaeological studies. 433 
When considering the impact of TB and leprosy on past populations, paleomicrobiological and 434 
bioarchaeological studies are showing that past populations faced biological and ecological 435 
heterogeneous landscapes. This makes it difficult to accept that a uniform (constantly present) 436 
cross protection or immunity was present between TB and leprosy.  437 
As mentioned above, more than one mycobacterial species can cause TB in humans where M. 438 
tuberculosis and M. bovis are the most common cause of illness (Stone et al. 2009); and within the 439 
same species we can also have genetic pools leading to different bacterial strains. It is crucial to 440 
know the pathogen strain affecting people, especially for TB, because the immunological response 441 
induced by M. tuberculosis is bacterial strain-dependent  (Wiens and Ernst 2016). Recently, two 442 
separate paleomicrobiological studies (from England and Hungary), show that different TB strains 443 
were present at varying periods of time (Kay et al. 2015; Muller et al. 2014; Roberts 2016). 444 
Clearly, as cited by other authors, changes in pathogen biology as well as in host immune 445 
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competence may modify TB morbidity and virulence (Sparacello et al. 2016) . As opposed to TB 446 
pathogens, different studies on ancient M. leprae genomes have shown that the DNA of the 447 
leprosy pathogen did not change significantly in Medieval Europe and therefore pathogen 448 
virulence cannot explain leprosy’s decline (Donoghue et al. 2015; Mendum et al. 2014; Roffey et 449 
al. 2017; Schuenemann et al. 2013; Schuenemann et al. 2018; Taylor et al. 2013). In addition, 450 
genetic studies in contemporary populations have shown that the immune genetic variance of the 451 
host is a key factor for the progress and outcome of leprosy infection, where candidate genes 452 
(alleles) such as human leukocyte antigen (HLA) and Toll-like receptors (TLR) show significant 453 
correlations with increased susceptibility to leprosy (Alcais et al, 2005; Mira 2006; Wong et al 454 
2010). Moreover, a recent study on ancient DNA from skeletal samples from a Medieval cemetery 455 
in Denmark also demonstrated a significant association between the HLA class II allele 456 
DRB1*15:01 and LL (Krause-Kyora et al. 2018). Interestingly, when correlating the immune 457 
genetic variance observed, in past and contemporary populations, with the presence of 458 
paleopathological evidence for leprosy, a complex scenario unfolds suggesting that we should 459 
incorporate the immune competence of each individual (with or without prior exposure to other 460 
mycobacterial species) to explain individual differences observed in different studies (Inskip et al. 461 
2015; Mendum et al. 2014). 462 
The skeletal data also show a complex landscape when considering the impact of TB and leprosy 463 
on past populations. The first problem is that around 5% of patients with leprosy today exhibit 464 
skeletal signs of the disease (Resnick and Niwayama 1995), and in TB, bone changes are described 465 
only in 3-5% of individuals with known diagnosis (Resnick and Niwayama 1995; Roberts and 466 
Buikstra 2003). Most skeletal markers or lesions (bilateral and symmetrical) are found in LL, and 467 
can be minimal or non-existent in TL (Roberts 2011) but in a study of records from leprosy 468 
hospital patients, bilateral or unilateral hand and foot bone involvement and no rhinomaxillary 469 
syndrome have been identified for a diagnosis of TL (Matos 2009). In the case of TL, where an 470 
extensive cell mediated immune response is present, many skeletons may not show any bone 471 
changes (Roberts 2011). Clearly, a skeleton without signs of infection could have experienced the 472 
infection but died before developing bone lesions; this suggests that skeletal remains with signs of 473 
TB or leprosy infection indicate that these people must have had a long lasting chronic infection 474 
(Roberts 2015). Here, we must consider different risk factors such as living conditions and diet 475 
that may affect the extent of skeletal involvement in both diseases (Dixon and Roberts 2001; 476 
Roberts 2015), and where the immune competence of an individual will also influence whether 477 
skeletal lesions will occur (Roberts 2015).  478 
We must reassess the situation that most archaeological skeletons are identified in LL. Therefore, a 479 
problem emerges here: we should predict a higher incidence of cross immunity for individuals 480 
with TL (with extensive cellular immune response) but most of the skeletal evidence is absent for 481 
this disease state, or at least (so far) cannot be recognized as such. Consequently, we propose that 482 
when studying the cross-immunity hypothesis using skeletal remains, we should carefully explore 483 
the immunological differences between TL and LL but, as pointed out by Wilbur and colleagues, 484 
more problems arise when most studies do not distinguish between these two disease states 485 
(Wilbur et al. 2002). Evidently, a complex and heterogeneous landscape emerges when 486 
contemporary epidemiological data show significant variation among populations for LL/TL ratios 487 
in the occurrence of leprosy (Hunter and Thomas 1984). Recognizing LL and TL (especially in 488 
paleopathological analysis) could be crucial when expecting (or not) cross immunity between TB 489 
and leprosy, where the presence of TL or LL can potentially inform us about the immunological 490 
status of each individual. For example, it was proposed that TB infection in living populations 491 
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could confer some protection to TL but not to LL (Leiker et al. 1968), and it was suggested that in 492 
the late Medieval period, leprosy did not disappear but just shifted to a higher frequency of TL. 493 
Perhaps also the number of people who experienced TB in the past has been significantly 494 
underestimated (probably more than leprosy) because a skeleton with no bone changes of TB (or 495 
leprosy) could have experienced the infection but died before expressing any skeletal marker for 496 
the disease (Roberts 2015; Wood et al. 1992). Interestingly, it was proposed that impaired cellular 497 
immunity could have led to a re-activation of an underlying latent TB infection, or to 498 
superinfection with M. tuberculosis, and to a speedier death. This would lead to a decline in the 499 
number of individuals experiencing leprosy and end with the observed phenomenon of its decline 500 
(Donoghue et al. 2005). Molecular evidence also supports the case for the underestimation of TB 501 
when using osteological data, where some individuals have tested positive for ancient DNA from 502 
M. tuberculosis but have no skeletal signs of the infection (Cooper et al. 2016; Donoghue et al. 503 
2005), and a similar case must be considered for leprosy. 504 
We must recognize that skeletal data should ideally be used to reconstruct the immune phenotype 505 
of each individual, ultimately helping to understand the clinical progression of each infection and 506 
their potential interaction. As mentioned above, in leprosy the immune competence of each 507 
individual plays a significant role in the infection’s progression and clinical manifestation (more 508 
than the direct interaction with TB). It has been proposed that a population with many generations 509 
of exposure to TB may produce stronger immune responses, greater survival, and a higher 510 
occurrence of bone changes in affected individuals (Roberts and Buikstra 2003). This would have 511 
an impact on leprosy progression if such individuals where later exposed to M. leprae.  Therefore, 512 
when exploring the cross-immunity hypothesis using archaeological skeletal markers of these 513 
infections, we must consider a model where consideration is made regarding the expected 514 
immunological shift generated by early exposure to TB, taking into account different levels of 515 
cellular immunity ultimately affecting the progress (or not) of leprosy infection. This model should 516 
include the immunological differences (and potential interplay) observed in latent and active TB, 517 
and in TL or LL in leprosy (Figure 2), along with the bio-social landscape. 518 
2.4 Heterogeneous biosocial landscapes and differential cross immunity: searching for a 519 
multifactorial model. 520 
While biology dictates a great proportion of the immune responses of an individual, we cannot rule 521 
out the role of environmental and social factors in such responses, especially when considering 522 
long lasting chronic infections, and this could be crucial, for example, when predicting or testing 523 
the potential role of TB in leprosy’s decline. Populations and individuals, today and in the past, are 524 
and were immersed within specific environments and social contexts that generated heterogeneous 525 
biological (immunological) landscapes, and we cannot consider that all populations in time and 526 
space represent identical immunological units (Crespo and Lawrenz 2014). 527 
Perhaps leprosy could be considered as one of the chronic infectious disease with the heaviest 528 
social burden, where susceptibility to and the clinical manifestation of leprosy have roots in social 529 
and cultural factors that affect overall health and immunity (White and Franco-Paredes 2015). 530 
While skeletal remains from cemeteries associated with hospitals, infirmaries, or poor houses 531 
could be strongly biased as a result of selective or differential mortality (Connell et al. 2012), 532 
bioarchaeological studies can teach us how heterogeneous social and ecological contexts could 533 
ultimately have impacted on the immune competence of different individuals or even whole 534 
populations. One of the main lessons from bioarchaeological reconstructions is to show, especially 535 
with leprosy, how different people and populations evoked (in time and space) different 536 
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experiences according to different variables such as sex, age, social status, and religion (Roberts 537 
2011). 538 
In Medieval Europe leprosy was not an isolated regional phenomenon, and large-scale institutional 539 
care in the form of leprosy hospitals or leprosaria were introduced, although the status and 540 
organization of such institutions varied in time and space. Moreover, unlike monastic institutions, 541 
there was not a regular plan or predefined lay out for leprosy hospitals (Roffey 2012). The 542 
organizational heterogeneity probably impacted on the diet, sanitation, care, treatment, and daily 543 
life of those who lived in these institutions  (Roffey 2012). Not only have institutional differences 544 
been observed during the peak of leprosy in Medieval Europe, but regional differences in attitudes 545 
towards people with leprosy were also common (Brenner 2010; Dematrie 2007; Rawcliffe 2006; 546 
Roberts 2011). Recent bioarchaeological analyses are also showing that, in some regions, 547 
segregation of those with leprosy is a more recent behavior than previously thought (Baker and 548 
Bolhofner 2014). Interestingly, as observed in past populations in South Asia, even within the 549 
same region, complex societal changes can also affect the social perception of an infectious 550 
disease, whose related pathogen perhaps, did not change at all (Robbins Schug 2016). Moreover, 551 
in India, one of the three areas of the world today with the highest rate of “new cases” of leprosy 552 
(WHO 2016), people in leprosy hospitals can represent an element of bias due to a higher risk of 553 
exposure to and developing TB (Rawson et al. 2014). Such social and institutional disparities, in 554 
time and space must have had a significant impact on disease progress and the overall health of 555 
people with leprosy (including immune competence). 556 
It is well recognized that the immune system presents a high degree of plasticity and requires a 557 
delicate energetic balance, and marked fluctuations in the immune response occur as a reaction to 558 
environmental and social factors during an individual’s lifetime (French et al. 2009).  Ecological 559 
immunology is an emerging discipline that helps us to understand how the immune response is 560 
both plastic and dynamic (McDade 2003; McDade 2005a), and we cannot extrapolate 561 
experimental data without carefully considering social and ecological factors. The main objective 562 
of ecological immunology (or ecoimmunology) is to study and explain natural variation in immune 563 
function, especially considering how biotic and abiotic factors contribute to such variation in 564 
immunity in free-living organisms (Martin et al. 2011). While the first studies were focused on 565 
non-human organisms, the discipline started expanding and including humans, with special 566 
attention on how individual life history can affect immune responses (McDade, 2003). Immunity 567 
can be costly, and defense mechanisms are regulated within the context of costs, ecological 568 
influences and constraints (Brock, 2014). For example, and important for the multifactorial model 569 
proposed in this study (Figure 3), early studies explored how chronic social stressors in childhood 570 
(i.e. family environment, caretaking attention) are associated with a higher average level of 571 
cortisol, which is found correlated with alterations of the immune function and increased 572 
frequency of infections (Flinn and England, 1995; Flinn and England, 2003). Status-related stress 573 
(also in part through the effects of cortisol), recently shown in forager-horticulturalists populations 574 
in Bolivia, can affect inflammatory responses, ultimately playing a role on the progress of different 575 
infectious diseases (VonRueden et al, 2014). It has also been proposed that immune function and 576 
sickness responses vary seasonally, where in some populations with TB the highest incidence 577 
occurs in winter (Nelson, 2004), and where one mechanism could be associated with the lowest 578 
bactericidal activity observed in some immune cells (neutrophils) during winter (Klink et al, 579 
2012). Interestingly, the season of birth might be another important factor that could influence 580 
susceptibility to TB because it could affect in utero nutrients, fetal/neonatal exposure to infection, 581 
or possible neonatal immunological resistance to TB (Miura et al, 1992). Thomas McDade 582 
14 
 
proposed the “eco-logics” of inflammation and the importance of early environments shaping the 583 
development and function of the human immune system, suggesting that comparative studies 584 
across different ecological settings are needed (McDade, 2012).  585 
The integration of ecological immunological and human health studies in living populations has 586 
developed extensively over the last 20 years, but more consistent integration of ecological 587 
immunology into paleopathological research is still pending and should be considered one of the 588 
next frontiers in bioarchaeological studies. When studying TB in skeletal samples, Wilbur and 589 
colleagues (2008) proposed that immunological, epidemiological, and archaeological data can be 590 
integrated to generate predictions for tuberculosis in skeletal samples, where the contributions of 591 
dietary proteins and iron can affect immune function and determine the course and outcome of 592 
infection (Wilbur et al 2008). We propose that this should also be a factor when determining the 593 
individual capacity to develop TB-leprosy cross immunity. Interestingly, Klaus and Tam (2009) 594 
studied the bioarchaeology of systemic stress in colonial Peru, proposing a complex model of 595 
systemic biological stress in Morrope, Peru, as shaped by postcontact population aggregation, 596 
where the interplay of different cultural and environmental stressors (i.e. increased proximity to 597 
waste, poor sanitation, contaminated water supplies) can ultimately affect the immune competence 598 
of individuals and intensify host-pathogen relationship (Klaus and Tam, 2009). While not 599 
formalizing integration of paleopathology with ecological immunology, but applicable to the 600 
objective of this manuscript, a recent article studying TB in medieval to early modern Denmark 601 
suggested that ecological and social factors explained changing patterns in TB prevalence 602 
(Dangavrd Pedersen et al 2018), where we propose that those ecological and social factors should 603 
be factored into studies when trying to understand the heterogeneous immune competence of 604 
populations in time and space. A recent paleopathological study on leprosy explored the 605 
association between childhood non-specific markers of stress and leprosy immunity in Medieval 606 
England, finding that immune processes were likely more influenced by maternal and early 607 
physiological stress than environmental factors later in life (Filipek-Ogden 2014). This is also 608 
relevant to the Developmental Origins Hypothesis of Health and Disease (Barker 1992). If early 609 
physiological stress leads to constant frailty, then the general level of functioning of the immune 610 
system can have a significant impact on the progress of leprosy in any one person (Boldsen 2005). 611 
Therefore, we can argue that early stress or constant frailty could also affect an individual’s 612 
capacity to develop cross immunity or not.  613 
As we previously discussed (Crespo et al. 2017), experimental protocols do not consider at all the 614 
systemic or whole organism immune competence, whereas skeletal analysis deals with 615 
pathological markers that reflect not only a clinical snapshot of skeletal health at death but the 616 
interaction of different cofounding risk factors for disease over a life time. Cross sectional studies 617 
in modern populations can also offer a biological and clinical foundation that could help an often 618 
sparse archaeological record when testing the model proposed in this manuscript. As explained 619 
earlier, LL patients have been shown to mount a lower cellular immunity and inflammatory 620 
response (i.e. lower TNFα response) and this could explain increased TB reactivation or 621 
dissemination (Rawson et al 2014), but most studies of modern populations that consider 622 
concomitant infection with TB and leprosy are case reports for one or few individuals (Ayra et al 623 
2016; Mangum et al 2018; Sendrasoa et al 2015; Verma et al 2015). However, some modern 624 
populations offer a unique opportunity to study disease interaction and concomitant infection, as 625 
recently analyzed in Marshallese, Arkansas, US, where high rates of TB and leprosy are present. 626 
The authors of this study concluded that while a study on a larger scale is needed, preliminary data 627 
are supportive of the existence of cross-immunity (Cardenas et al, 2016). 628 
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As recently proposed by one of the authors of this study (FC), understating the heterogeneous 629 
immunological landscapes detected in different populations in time and space requires a new 630 
dialogue to develop between scientific and social disciplines (Crespo and Lawrenz 2014). A 631 
comprehensive bioarchaeological analysis of the interaction of TB and leprosy in past populations 632 
can help with such complex reconstructions. Heightened or weakened innate or cellular immune 633 
responses influenced by ecological factors can ultimately play a role in the progression (or not) of 634 
cross protection.  Ecological immunology is reminding us that shaping the immunological 635 
phenotype of an individual starts early in life (McDade 2005b; McDade et al. 2010). Therefore, in 636 
an ideal world we should also consider (and reconstruct) early ecological and social contexts for 637 
the life of each individual studied.  638 
In our final multifactorial model, we consider different scenarios when predicting cross-immunity, 639 
or not (Figure 3). For example, during latent infection, a potential balance of both inflammatory 640 
and anti-inflammatory factors can be generated. Further, in addition to biological factors, social 641 
and ecological factors can also affect this balance to produce the final impact on the immune 642 
competence of individuals, and ultimately the development of cross-immunity. When diagnosing 643 
leprosy in paleopathology, it has been proposed that there is a need to think about the 644 
epidemiological process, and develop a better understanding of the dynamic relationship between 645 
pathogens and human populations (Boldsen 2001). Perhaps it is time to suggest that the complex 646 
nature of immunological variance among human populations should be considered in 647 
interpretations of past health, especially when considering the complex interaction of TB and 648 
leprosy. As reiterated recently by Spigelman and Rubini, the origin of TB and leprosy cross 649 
immunity is still controversial, but perhaps the most conclusive clinical fact is that, with some 650 
degree of variability, leprosy may be prevented following BCG vaccination (Spigelman and 651 
Rubini 2016). 652 
 653 
3. CONCLUSIONS  654 
When exploring or testing the TB-leprosy cross immunity temporally and geographically, we 655 
propose that different inherent factors should be considered, such as novel findings in innate 656 
immunity memory and ecological immunology. When studying the individual capacity to develop 657 
(or not) cross immunity, biological, ecological, and social factors should not be considered to work 658 
in isolation but synergistically. Such a complex and multifactorial approach presented in the 659 
current study shows that past populations do not represent homogeneous immunological 660 
landscapes, and therefore it is likely that leprosy in Medieval Europe did not show a uniform 661 
decline, especially when considering disease interactions, and especially TB. We propose that 662 
bioarchaeological reconstructions that take into consideration experimental immunological data to 663 
explain underlying cellular and molecular mechanisms present a unique opportunity to develop a 664 
more comprehensive analysis of the complex multifactorial process involved in TB-leprosy cross 665 
immunity. 666 
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Figure 1: Summarized rationale for linking a chronic exposure to different mycobacterial species   1140 
               (except M. leprae) and a systemic inflammatory shift that either can generate protection   1141 
               to later leprosy (M. leprae); or predispose leprosy clinical phenotype towards  1142 
               tuberculoid leprosy (TL). 1143 
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Figure 2: Proposed model to integrate the expected immunological shift generated   1202 
                by an early exposure to tuberculosis, taking into consideration different levels of     1203 
                cellular immunity (hyper- or hypoactivation) and the clinical progress expected for  1204 
                leprosy (TL or LL) 1205 
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Figure 3: Proposed multifactorial model to predict the progress of cross-immunity between 1222 
tuberculosis and leprosy when taking into consideration the regulation of immune 1223 
activation due to different biological, ecological, and social factors. 1224 
               Different grey colors help to follow the conditions and predict “enhanced or decreased 1225 
immune competence-IC”, and finally inducing (or not) cross immunity. 1226 
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